X4 PHARMACEUTICALS INC's ticker is XFOR and the CUSIP is 98420X103. A total of 55 filers reported holding X4 PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $50,843 | -18.4% | 46,645 | +45.2% | 0.00% | – |
Q2 2023 | $62,326 | +1038666.7% | 32,127 | +458857.1% | 0.00% | – |
Q1 2023 | $6 | -33.3% | 7 | -22.2% | 0.00% | – |
Q4 2022 | $9 | -99.9% | 9 | 0.0% | 0.00% | – |
Q3 2022 | $15,000 | +66.7% | 9 | 0.0% | 0.00% | – |
Q2 2022 | $9,000 | -96.8% | 9 | -94.4% | 0.00% | – |
Q1 2022 | $280,000 | -56.0% | 160 | -42.4% | 0.00% | – |
Q4 2021 | $637,000 | -59.2% | 278 | -5.8% | 0.00% | – |
Q3 2021 | $1,561,000 | -48.0% | 295 | -36.1% | 0.00% | – |
Q2 2021 | $3,003,000 | -93.8% | 462 | -91.8% | 0.00% | – |
Q1 2021 | $48,293,000 | +142.1% | 5,609 | +80.8% | 0.00% | – |
Q4 2020 | $19,946,000 | -18.2% | 3,102 | -13.9% | 0.00% | – |
Q3 2020 | $24,392,000 | +332.6% | 3,603 | +495.5% | 0.00% | – |
Q2 2020 | $5,639,000 | -87.9% | 605 | -87.0% | 0.00% | – |
Q1 2020 | $46,520,000 | +159.6% | 4,652 | +177.7% | 0.00% | – |
Q4 2019 | $17,922,000 | +33.0% | 1,675 | +58.0% | 0.00% | – |
Q3 2019 | $13,473,000 | +772.0% | 1,060 | +929.1% | 0.00% | – |
Q2 2019 | $1,545,000 | – | 103 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Bain Capital Life Sciences Investors, LLC | 12,202,510 | $10,616 | 1.33% |
Tri Locum Partners LP | 3,878,484 | $3,374,281 | 1.03% |
Lynwood Capital Management Inc. | 900,000 | $783,000 | 0.71% |
NEA Management Company, LLC | 11,736,793 | $10,211,010 | 0.71% |
Parkman Healthcare Partners LLC | 2,797,147 | $2,433,518 | 0.53% |
SCOGGIN MANAGEMENT LP | 484,796 | $567,025 | 0.33% |
New Leaf Venture Partners, L.L.C. | 335,000 | $291,450 | 0.24% |
Ghost Tree Capital, LLC | 850,000 | $740,000 | 0.22% |
Perceptive Advisors | 4,545,454 | $3,954,545 | 0.12% |
Orbimed Advisors | 5,817,726 | $5,061,422 | 0.10% |